Figure 1.

CELF2 Expression Is Downregulated in Ovarian Cancer and Predicts Poor Prognosis

(A) Method used to screen differentially expressed RBPs in ovarian cancer through a comprehensive analysis of three datasets. (B) The expression of 28 key RBPs in our microarray data from 10 ovarian cancer tissues and 8 normal ovarian tissues is presented in a heatmap. (C) Expression of the CELF2 mRNA in 50 ovarian cancer specimens and 50 normal ovarian surface epithelial specimens analyzed using qRT-PCR (p = 0.0005). (D) Western blot showing CELF2 levels in six ovarian cancer tissues and six normal ovarian tissues. (E) Representative images and proportions of negative, weakly positive, moderately positive, and strongly positive CELF2 immunohistochemical (IHC) staining in normal ovarian tissues (left panel) and ovarian cancer tissues (right panel) (scale bars, 40 μm). (F) Representative images of negative, weakly positive, moderately positive, and strongly positive IHC staining for CELF2 in ovarian cancer tissues (scale bars, 200 μm and 40 μm). (G) A Kaplan-Meier analysis was performed to assess the associations between CELF2 expression and the OS (p = 0.0096) and PFS (p = 0.0014) of patients with ovarian cancer. Data are presented as mean ± SEM.